145106-43-0

Basic information

• Product Name: (1S,2S)-trans-N-Boc-2-aminocyclopentanol
• Synonyms: (1S,2S)-trans-N-Boc-2-aminocyclopentanol;tert-butyl (1S,2S)-2-hydroxycyclopentylcarbamate;((1S,2S)-2-Hydroxycyclopentyl)carbamic acid tert-butyl ester;tert-Butyl N-((2S,1S)-2-hydroxycyclopentyl)carbamate;(1S,2S)-trans-N-Boc-2-aminocyclopentanol 99%
• CAS NO: 145106-43-0
• Molecular Formula: C₁₀H₁₉NO₃
• Molecular Weight: 201.26
• Product Categories: Amino Alcohols;Chiral Building Blocks;Organic Building Blocks;apis
• Mol File: 145106-43-0.mol

Chemical Properties

• Melting Point: 87.0℃
• Boiling Point: 320.8±31.0 °C(Predicted)
• Appearance: /
• Density: 1.08±0.1 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: 2-8°C
• PKA: 12.09±0.40(Predicted)
• BRN: 5810036
• CAS DataBase Reference: (1S,2S)-trans-N-Boc-2-aminocyclopentanol(CAS DataBase Reference)
• NIST Chemistry Reference: (1S,2S)-trans-N-Boc-2-aminocyclopentanol(145106-43-0)
• EPA Substance Registry System: (1S,2S)-trans-N-Boc-2-aminocyclopentanol(145106-43-0)

Safety Data

• Hazard Codes: Xn,N
• Statements: 22-50
• Safety Statements: 61
• RIDADR: UN 3077 9/PG 3
• WGK Germany: 3
• Hazardous Substances Data: 145106-43-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(1S,2S)-trans-N-Boc-2-aminocyclopentanol is used as a reactant for the asymmetric synthesis of constrained (-)-S-adenosyl-L-homocysteine (SAH) analogs. These analogs serve as DNA methyltransferase inhibitors, which are important in the development of drugs targeting various diseases, including cancer and neurological disorders.
Used in Chemical Synthesis:
(1S,2S)-trans-N-Boc-2-aminocyclopentanol is used as a key intermediate in the synthesis of various complex organic molecules, such as natural products and pharmaceutical compounds. Its unique stereochemistry and functional groups make it a valuable building block for creating novel molecules with potential applications in various fields.
Used in Research and Development:
(1S,2S)-trans-N-Boc-2-aminocyclopentanol is employed as a research tool in the development of new synthetic methods and strategies for the preparation of biologically active molecules. Its unique structure allows chemists to explore new reaction pathways and develop innovative approaches to synthesize complex molecules with potential therapeutic applications.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 930-45-0 (1S,2S)-2-aminocyclopentanol 
• 125356-51-6 (1S,2S)-trans-2-azidocyclopentanol 
• 68327-04-8 (1S,2S)-2-aminocyclopentanol hydrochloride 
• 88807-02-7 (±)-trans-2-azidocyclopentanol 
• 1430230-60-6 tert-butyl N-[(1S,2S)-2-trimethylsilyloxycyclopentyl]carbamate 
• 756874-86-9 (1S,2S)-2-azido-cyclopentyl butyrate 
• 181657-56-7 (1S,2S)-2-(benzyloxy)cyclopentanamine 
• 445479-00-5 (1S, 2S)-2-benzyloxy-cyclopentyl-carbamic acid tert-butyl ester 

Downstream Products

• 145106-46-3 (S)-N-tert-butoxycarbonyl-2-aminocyclopentanone 
• 445479-01-6 (1R,2S)-2-tert-Butoxycarbonylaminocyclopentylamine 

Relevant articles and documents

Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction

Inhibition of the menin-mixed lineage leukemia (MLL) protein-protein interaction is a promising new therapeutic strategy for the treatment of acute leukemia carrying MLL fusion (MLL leukemia). We describe herein our structure-based design, synthesis, and evaluation of a new class of small-molecule inhibitors of the menin-MLL interaction (hereafter called menin inhibitors). Our efforts have resulted in the discovery of highly potent menin inhibitors, as exemplified by compound 42 (M-89). M-89 binds to menin with a Kd value of 1.4 nM and effectively engages cellular menin protein at low nanomolar concentrations. M-89 inhibits cell growth in the MV4;11 and MOLM-13 leukemia cell lines carrying MLL fusion with IC50 values of 25 and 55 nM, respectively, and demonstrates >100-fold selectivity over the HL-60 leukemia cell line lacking MLL fusion. The determination of a co-crystal structure of M-89 in a complex with menin provides the structural basis for their high-affinity interaction. Further optimization of M-89 may lead to a new class of therapy for the treatment of MLL leukemia.

COMPOUNDS, COMPOSITIONS AND METHODS FOR SYNTHESIS

The present disclosure, among other things, provides technologies for synthesis, including reagents and methods for stereoselective synthesis. In some embodiments, the present disclosure provides compounds useful as chiral auxiliaries. In some embodiments, the present disclosure provides reagents and methods for oligonucleotide synthesis. In some embodiments, the present disclosure provides reagents and methods for chirally controlled preparation of oligonucleotides. In some embodiments, technologies of the present disclosure are particularly useful for constructing challenging internucleotidic linkages, providing high yields and stereoselectivity.

CHIRAL DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES

The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer, pain, neurological diseases, autoimmune diseases, and inflammation.

PIPERIDINES AS MENIN INHIBITORS

The present disclosure provides compounds represented by Formula (I): (Formula(I)) and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R2, R3a, R3b, A, G, X, and Y are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer.

Copper-Catalyzed Asymmetric Borylative Ring Opening of Diazabicycles

Highly enantioselective, copper-catalyzed ring opening of bicyclic hydrazines using a diboron reagent was accomplished with (R,R)-taniaphos as a chiral ligand. Desymmetrization of various bicyclic hydrazines by boryl substitution afforded 3-Bpin-4-hydrazino-cyclopentene derivatives with enantioselectivity up to >99% under mild conditions. The resulting allylic boron products were utilized in further organic transformations. Kinetic resolution of a racemic bicyclic oxazine gave useful information about the relative rates of C-O and C-N bond cleavage.

IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS

The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, G, T, Y1, Y2, Y3, and Y4 are as defined herein.

Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core

New series of pyrrolidine mercaptosulfide, 2-mercaptocyclopentane arylsulfonamide, and 3-mercapto-4-arylsulfonamidopyrrolidine matrix metalloproteinase inhibitors (MMPIs) were designed, synthesized, and evaluated. Exhibiting unique properties over other MMPIs (e.g., hydroxamates), these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including MMP-2 (～2 to 50 nM), MMP-13 (～2 to 50 nM), and MMP-14 (～4 to 60 nM). Additionally these compounds are selective to intermediate- and deep-pocket MMPs but not shallow-pocketed MMPs (e.g., MMP-1, ～850 to >50 000 nM; MMP-7, ～4000 to >25 000 nM). Our previous work with the mercaptosulfide functionality attached to both cyclopentane and pyrrolidine frameworks demonstrated that the cis-(3S,4R)-stereochemistry was optimal for all of the MMPs tested. However, in our newest compounds an interesting shift of preference to the trans form of the mercaptosulfonamides was observed with increased oxidative stability and biological compatibility. We also report several kinetic and biological characteristics showing that these compounds may be used to probe the mechanistic activities of MMPs in disease.

SELECTIVE ANDROGEN RECEPTOR MODULATORS

The present invention provides novel selective androgen receptor modulators and their salts and pharmaceutical compositions thereof.

SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa

In the search of Factor Xa (FXa) inhibitors structurally different from the pyrazole-based series, we identified a viable series of enantiopure cis-(1R,2S)-cycloalkyldiamine derivatives as potent and selective inhibitors of FXa. Among them, cyclohexyldiam

CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS

The present application describes cyclic diamino compounds, derivatives thereof, and pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.